molecules transparent

Industry Program

Optimising Patient Selection in Early-Stage Lung Cancer: Evolving Pathology Practices and the MDT Approach

Monday 24 June – 12:30 – 13:30
🏠︎ Zaragoza Plenary Room 

Monday 24 June – 12:30 – 13:30

Chair:  Alexander Yarunin

Welcome and Introduction
Alexander Yarunin

Molecular Pathology in the Setting of Early-Stage NSCLC: Exploring Contrasts in Practice with Advanced Disease
Paul Hofman, Nice Sophia Antipolis University, France

Navigating Diagnostic Dilemmas in Early-Stage NSCLC: the MDT Approach
Beatriz Bellosillo

Interactive Discussion
Alexander Yarunin

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments

Tuesday 25 June – 9:45 – 10:45
🏠︎ Zaragoza Plenary Room 

Tuesday 25 June – 9:45 – 10:45
Chair:  Parth Sitlani, Invivoscribe Associate Director, Commercial – EMEA & APAC

Introduction 
Parth Sitlani, Invivoscribe

Beyond Systematic Memory B-Cell Archiving: Mining B-Cell Receptor Repertoires for Antigen-Specific Clones and Tumor Cell Precursors
Dr. Artur Kibler, Institute of Cell Biology, University of Duisburg-Essen, Essen, Germany

Implementation of NGS-Based Clonality and MRD Testing in a High Throughput Environment
Wayne Yu, Memorial Sloan Kettering Cancer Center, New York, NY, US

Q&A Session

From DNA to Insights: Uncovering the Overlooked with Innovative NGS Technology for MRD Assessment

Tuesday 25 June – 9:45 – 10:45
🏠︎ Zaragoza Breakout Room

Tuesday 25 June – 9:45 – 10:45

Chair:  Jose Maria Belloso, PhD
Global Product Manager – HemOnc, SOPHiA GENETICS, Rolle, Switzerland

Optimizing Acute Myeloid Leukemia Monitoring: A Novel NGS Application for Measurable Residual Disease (MRD) Assessment
Silvia Salmoiraghi, PhD Biologist, Ultra-specialist Laboratory of Clinical Pathology-Hematology, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy

Staying Ahead of Disease Response with the Analytical Capabilities of the SOPHiA DDM™ Platform
Jose Maria Belloso, PhD
Global Product Manager – HemOnc, SOPHiA GENETICS, Rolle, Switzerland

From Detection to Action: Enhancing the Integrity of HRD Tests in Ovarian Cancer and Embracing ctDNA in Prostate Cancer

Tuesday 25 June – 13:00 – 14:00
🏠︎ Zaragoza Breakout Room

Tuesday 25 June – 13:00 – 14:00

Chair:  Prof. Jose Lopez Guerrero

Welcome and Introductions
Prof. Jose Lopez Guerrero

Confidence and Competence: Ensuring Excellence in HRD Testing in Ovarian Cancer
Prof. Nicole Pfarr, TUM · Institut für Allgemeine Pathologie und Pathologische Anatomie

ctDNAin the Spotlight: Transforming the Landscape of Prostate Cancer Diagnostics
Prof. Umberto Malapelle, University of Naples Federico II | UNINA · Department of Public Health

Hot Topics – Variant Interpretation
Dr. David Olmos

Discussion, Q&A and Closing Remarks
Prof. Jose Lopez Guerrero

Integrating ctDNA Analysis for Targeted Therapy in Metastatic Breast Cancer

Tuesday 25 June – 13:00 – 14:00
🏠︎ Zaragoza Plenary Room

Tuesday 25 June – 13:00 – 14:00
Chair:  Dr. Alexander Sartori, Sr. Manager Scientific Affairs, Agena Bioscience

Integrating ctDNA Analysis for Targeted Therapy in Metastatic Breast Cancer
Dr. Pierre-Jean Lamy, Labosud-Ocbiologie, Imagenome, Montpellier, France

Sensitive Mutation Profiling in Tissue and Liquid Biopsy: Detect Clinically Relevant Biomarkers in Difficult Samples Quickly and Cost-Effectively
Dr. Alexander Sartori, Sr. Manager Scientific Affairs, Agena Bioscience

Why Is Comprehensive Testing Essential in Cancer Care? 

Wednesday 26 June – 13:00 – 14:00
🏠︎ Zaragoza Plenary Room

Wednesday 26 June – 13:00 – 14:00
Chair:  Kara O’Brien, Novartis, Executive Director, Global Precision Diagnostics

Welcome & Introductions
Kara O’Brien, Executive Director, Global Precision Diagnostics, Novartis

Nicole Pfarr, AMP International Affairs Committee Member, Head of Pathology, Institute of Pathology, TUM School of Medicine and Health, Technical University of Munich, Germany

The Overwhelming Data in Support of the Use of Comprehensive Genomic Testing to Improve Patient Outcomes
Luis Paz-Ares, Head of Medical Oncology Department, University Hospital, Madrid, Spain

Implementing Comprehensive Genomic Testing into Routine Practice
Fernando Lopez-Rios, AMP International Affairs Committee Member, Chief of Molecular Diagnostic, Department of Pathlogy, University Hospital, Madrid, Spain

The Role of Tissue and Liquid Biopsy in Comprehensive Genomic Testing
Paul Hofman, Professor of Pathology and Head of the Laboratory of Clinical and Experimental Pathology, Nice Sophia Antipolis University, France

Discussion, Q&A, Closing
Nicole Pfarr, AMP International Affairs Committee Member, Head of Pathology, Institute of Pathology, TUM School of Medicine and Health, Technical University of Munich, Germany 

Federico Monzon

Federico A. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests, including leading studies on prostate and renal cancer genomics and the validation of one of the first FDA-cleared gene expression clinical assays for the diagnosis of tumors of unknown origin while at the University of Pittsburgh and Houston Methodist Hospital. At Invitae and Baylor Genetics laboratories, he pioneered the use of panel testing for hereditary cancers as well as cancer exome sequencing.

Dr. Monzon is a consultant on medical and scientific strategy for companies in the diagnostic space. Currently, he is Chief Medical Officer (CMO) at Delphi Diagnostics, a laboratory focused on providing genomic tools for the management of breast cancer patients. Prior to that, he served as CMP for Castle Diagnostics and served as Medical Director of Oncology and Medical Director for Latin America at Invitae Corporation. Previously, Dr. Monzon served as Director of Pathology at the Cancer Genetics Laboratory at Baylor College of Medicine. He earned his M.D. from the Universidad Nacional Autónoma de México (UNAM) and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. Dr Monzon was the 2017 President of the Association for Molecular Pathology (AMP) and continues to be engaged in AMP and other professional societies to shape the future of clinical genomic medicine.

Soon!